Use of Functional MRI to Assess Functional Hypothalamic Activation in Response to Diazoxide

Inclusion Criteria: * Type 2 Diabetes (T2D) * Age: Between 21 and 70 y.o. * BMI: \<35 * A1c 8.0-12.0% * Negative drug screen * Not suffering from proliferative retinopathy, significant diabetic renal disease or severe neuropathy (including cardiovascular and gastrointestinal autonomic dysfunction) * Healthy (ND) * Age: Between 21 and 70 y.o. * BMI: \<30 * Negative drug screen * No family history of diabetes among first-degree relatives (mother, father) Exclusion Criteria: * Age: Under 21 or over 70 y.o. * BMI: \>35 for T2D and \>30 for ND * Hypertension * Severe polydipsia and polyuria * Uncontrolled hyperlipidemia * Clinically significant liver dysfunction * Clinically significant kidney dysfunction * Anemia * Clinically significant leukocytosis or leukopenia * Clinically significant thrombocytopenia or thrombocytosis * Coagulopathy * Positive urine drug screen * Urinalysis: Clinically significant abnormalities * Clinically significant electrolyte abnormalities * Smoking \>10 cig/day * Alcohol: Men \>14 drinks/wk or \> 4 drinks/day, Women \>7 drinks/wk or \>3 drinks/day * History of chronic liver disease, active hepatitis infection, HIV/AIDS, chronic kidney disease (stage 3 or greater), active cancer, cardiovascular disease or other heart disease, systemic rheumatologic conditions, seizures, bleeding disorders, muscle disease * Surgeries that involve removal of endocrine glands except for thyroidectomy * Pregnant women * Subject enrolled in another stu…